Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy.

Yip C, Landau D, Kozarski R, Ganeshan B, Thomas R, Michaelidou A, Goh V.

Radiology. 2014 Jan;270(1):141-8. doi: 10.1148/radiol.13122869. Epub 2013 Oct 28.

PMID:
23985274
2.

Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival.

Ng F, Ganeshan B, Kozarski R, Miles KA, Goh V.

Radiology. 2013 Jan;266(1):177-84. doi: 10.1148/radiol.12120254. Epub 2012 Nov 14.

PMID:
23151829
3.

Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer.

Yip C, Davnall F, Kozarski R, Landau DB, Cook GJ, Ross P, Mason R, Goh V.

Dis Esophagus. 2015 Feb-Mar;28(2):172-9. doi: 10.1111/dote.12170. Epub 2014 Jan 27.

PMID:
24460831
4.

Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy.

Zhang H, Graham CM, Elci O, Griswold ME, Zhang X, Khan MA, Pitman K, Caudell JJ, Hamilton RD, Ganeshan B, Smith AD.

Radiology. 2013 Dec;269(3):801-9. doi: 10.1148/radiol.13130110. Epub 2013 Oct 28.

PMID:
23912620
5.

Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival.

Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K.

Clin Radiol. 2012 Feb;67(2):157-64. doi: 10.1016/j.crad.2011.08.012. Epub 2011 Sep 23.

PMID:
21943720
6.

Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker.

Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA.

Radiology. 2011 Oct;261(1):165-71. doi: 10.1148/radiol.11110264. Epub 2011 Aug 3.

PMID:
21813743
7.

CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes.

Lubner MG, Stabo N, Lubner SJ, del Rio AM, Song C, Halberg RB, Pickhardt PJ.

Abdom Imaging. 2015 Oct;40(7):2331-7. doi: 10.1007/s00261-015-0438-4.

PMID:
25968046
8.

Non-small cell lung cancer: histopathologic correlates for texture parameters at CT.

Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA.

Radiology. 2013 Jan;266(1):326-36. doi: 10.1148/radiol.12112428. Epub 2012 Nov 20.

PMID:
23169792
9.

Prognostic value of computed tomography texture features in non-small cell lung cancers treated with definitive concomitant chemoradiotherapy.

Ahn SY, Park CM, Park SJ, Kim HJ, Song C, Lee SM, McAdams HP, Goo JM.

Invest Radiol. 2015 Oct;50(10):719-25. doi: 10.1097/RLI.0000000000000174.

PMID:
26020832
10.

Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer.

Fried DV, Tucker SL, Zhou S, Liao Z, Mawlawi O, Ibbott G, Court LE.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):834-42. doi: 10.1016/j.ijrobp.2014.07.020. Epub 2014 Sep 11.

11.

MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy.

Nougaret S, Rouanet P, Molinari N, Pierredon MA, Bibeau F, Azria D, Lemanski C, Assenat E, Duffour J, Ychou M, Reinhold C, Gallix B.

Radiology. 2012 May;263(2):409-18. doi: 10.1148/radiol.12111263. Epub 2012 Mar 21.

PMID:
22438364
12.

Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis?

Ng F, Kozarski R, Ganeshan B, Goh V.

Eur J Radiol. 2013 Feb;82(2):342-8. doi: 10.1016/j.ejrad.2012.10.023. Epub 2012 Nov 26.

PMID:
23194641
13.

Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.

Parikh J, Selmi M, Charles-Edwards G, Glendenning J, Ganeshan B, Verma H, Mansi J, Harries M, Tutt A, Goh V.

Radiology. 2014 Jul;272(1):100-12. doi: 10.1148/radiol.14130569. Epub 2014 Mar 19.

PMID:
24654970
14.

Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.

Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.

Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60. Review.

PMID:
15464463
15.

Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.

Ishihara R, Yamamoto S, Iishi H, Takeuchi Y, Sugimoto N, Higashino K, Uedo N, Tatsuta M, Yano M, Imai A, Nishiyama K.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):123-9. doi: 10.1016/j.ijrobp.2009.01.038. Epub .

PMID:
19386426
16.

Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer.

Hyun SH, Ahn HK, Park YH, Im YH, Kil WH, Lee JE, Nam SJ, Cho EY, Choi JY.

Radiology. 2015 Apr;275(1):235-44. doi: 10.1148/radiol.14141129. Epub 2014 Dec 11.

PMID:
25496075
17.

CT staging of esophageal carcinoma in patients treated by primary radiation therapy and chemotherapy.

Unger EC, Coia L, Gatenby R, Kessler H, Hartz W, Clair M, Broder G.

J Comput Assist Tomogr. 1992 Mar-Apr;16(2):235-9.

PMID:
1545019
18.

Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.

Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1484-93.

PMID:
15590179
19.

Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer.

Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P.

Am J Gastroenterol. 2007 Nov;102(11):2557-63. Epub 2006 Aug 4.

PMID:
17680847
20.

Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.

Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):656-64.

PMID:
15708243
Items per page

Supplemental Content

Write to the Help Desk